InVivo Therapeutics Adds to Executives’ Responsibilities

InVivo Therapeutics Holdings Corp. has expanded responsibilities for three members of its senior management team. The additional functional responsibilities, now at the senior management level, include operations, project management, and reimbursement planning.

William D’Agostino has been appointed senior vice president, operations. Prior to his new responsibilities, he held the position of vice president, manufacturing & engineering. D’Agostino joined InVivo in September 2012. Previously, he held the position of vice president, engineering at Angiotech Pharmaceuticals which included running all product development and engineering activities across their international facilities. He also worked for Covidien for fifteen years where he gained extensive experience with the development, synthesis and clinical production of bioabsorbable polymers. D’Agostino is a co-author of the book, “Regulatory Strategies for Combination Products.” He holds fourteen U.S. and European patents for medical devices on which he co-invented. Bill is a Licensed Professional Engineer and holds an MBA from the University of Dallas and a B.S. in both chemical engineering and materials engineering from the University of Connecticut.

Kristin Neff has been appointed vice president, clinical operations & project management. Previously, she held the position of vice president, clinical operations. Neff joined InVivo in August 2013 from TARIS Biomedical where she served as senior director, clinical operations. Prior to that, she was vice president, clinical affairs at ConforMIS Inc. and director of clinical project management at HeartWare Inc. Neff has an M.S. in biomedical engineering from Boston University and a B.S. in electrical engineering from University of Massachusetts, Amherst. Neff is a noted presenter at many conferences including Clinical Trials New England, the Project Management Institute and the Drug Information Association.

Lisa Crockett has been appointed vice president, regulatory affairs & reimbursement planning. Previously, her vice president’s title only covered regulatory affairs. Crockett joined InVivo in June of 2013 from Genzyme, where she most recently served as associate director of regulatory affairs. She holds an M.S. in regulatory affairs from Northeastern University and a B.S. from Johnson and Wales University. Crockett is a part-time instructor in the Master’s Degree Program in Regulatory Affairs at Northeastern University.

All three members of the senior management team will report to CEO, Mark Perrin.

“Following yesterday’s announcement of our new research and development strategy and the future direction of the company, it is critical to have these key functional responsibilities at the senior management level,” Perrin said. “Recognizing the valuable contributions that have been made by these three individuals, it is gratifying to have them assume such important additional responsibilities and is yet another example of the building and strengthening of our leadership team.”

InVivo Therapeutics is a biomaterials and biotechnology company with a focus on treatment of spinal cord injuries.